---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040564"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:49:04.551628+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium Q2 2023 net loss narrows to $3.3M; cash $48.4M; stock repurchase authorized

## Summary
- Revenue of $9.1M from Ono partnership; net loss $0.10/sh vs $0.41/sh loss year ago.
- Cash and investments $48.4M at June 30; fully prepaid and retired debt facility.
- Authorized $7.5M stock repurchase program; cash runway expected into 2025.
- Promoted Dr. Maple Fung to Chief Medical Officer; EQ101 alopecia areata data due 2H 2023.
- Ono option for itolizumab could bring ~$35M; EQUALISE lupus nephritis topline early 2024.

## SEC filing metadata
- accession: 0000950170-23-040564
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017023040564/0000950170-23-040564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017023040564/eq-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040564
- JSON: https://secwatch.observer/filing/0000950170-23-040564.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.